How do you convert from co-beneldopa (Madopar®) prolonged-release capsules to dispersible tablets?

Samantha Owen, Principal Pharmacist Critical Evaluation and UKMi Medicines Q&A Lead, Southampton Medicines Advice Service, University Hospital of Southampton NHS Foundation TrustPublished Last updated See all updates

For patients taking the prolonged-release preparation of co-beneldopa (Madopar® CR), there may be clinical situations when an alternative formulation of co-beneldopa needs to be considered e.g. if swallowing difficulties (dysphagia) develop. Co-beneldopa dispersible tablets (Madopar® Dispersible) are the formulation of choice for patients who are no longer able to swallow the prolonged-release capsules.

This Medicines Q&A offers advice on how to convert from Madopar CR capsules to the dispersible tablets.

Attachments

Change history

  1. Added "dysphagia" to body text to aid search for this article
  1. Published